DROPERIDOL VERSUS HALOPERIDOL FOR CHEMICAL RESTRAINT OF AGITATED AND COMBATIVE PATIENTS

被引:127
作者
THOMAS, H
SCHWARTZ, E
PETRILLI, R
机构
[1] Department of Emergency Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC
关键词
droperidol; haloperidol;
D O I
10.1016/S0196-0644(05)82660-5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: To compare two related pharmacological agents used for the chemical restraint of agitated and combative patients. Design and setting: A randomized, double-blind, prospective study was carried out in patients requiring physical restraint in a university hospital emergency department. Participants: Sixty-eight violent or agitated adult patients whom the attending physician believed would benefit from chemical restraint to protect the patient and staff and to expedite evaluation. Intervention: Twenty-one participants were administered 5 mg haloperidol IM; 26 were administered 5 mg droperidol IM; 12 were administered haloperidol IV; and nine were administered 5 mg droperidol IV. Results: All patients were rated on a five-point combativeness scale at five, ten, 15, 30, and 60 minutes after the study drug was given. Vital signs also were recorded at these times. IM droperidol decreased combativeness significantly more than IM haloperidol at ten (P = .006), 15 (P = .01), and 30 (P = .04) minutes. There was no significant difference between the two drugs when given by the IV route (beta at the 5% confidence level, P = .78). Conclusion: In equal IM doses (5 mg), droperidol results in more rapid control of agitated patients than haloperidol, without any increase in undesirable side effects.
引用
收藏
页码:407 / 413
页数:7
相关论文
共 31 条
[1]  
Dubin, Feld, Rapid tranquilization of the violent patient, Am J Emerg Med, 7, pp. 313-320, (1989)
[2]  
Clinton, Sterner, Stelmachers, Et al., Haloperidol for sedation of disruptive emergency patients, Ann Emerg Med, 16, pp. 319-322, (1987)
[3]  
Donlon, Hopkin, Tupin, Overview: Efficacy and safety of the rapid neuroleptization method with injectable haloperidol, Am J Psychiatr, 136, pp. 273-278, (1979)
[4]  
Cressman, Plostnieks, Johnson, Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration, Anesthesiology, 38, pp. 363-369, (1973)
[5]  
Janssen, Niemegeers, Schellekens, Et al., The pharmacology of Dehydrobenzperidol, a new potent and short acting neuroleptic agent chemically related to halo-peridol, Arzneimittelforschung, 13, pp. 205-211, (1963)
[6]  
Ayd, Parenteral (IM/IV) droperidol for acutely disturbed behavior in psychotic and non-psychotic individuals, Int Drug Ther Newsletter, 15, pp. 13-16, (1980)
[7]  
Resnick, Burton, Droperidol vs haloperidol in the initial management of acutely agitated patients, J Clin Psychiatr, 45, pp. 298-299, (1984)
[8]  
Cocito, Ambrosini, Arata, Et al., Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol, Arzneimittelforschung, 20, pp. 1119-1125, (1970)
[9]  
Hooper, Minter, Droperidol in the management of psychiatric emergencies, J Clin Psychopharmacol, 3, pp. 262-263, (1983)
[10]  
van Leeuwen, Molders, Sterkmans, Et al., Droperidol in acutely agitated patients. A double blind placebo-controlled study, J Nerv Ment Dis, 164, pp. 280-283, (1977)